Duality Biotherapeutics, Inc. (9606) Price & Analysis

Compare

3 Followers

9606 Stock Chart & Stats

HK$361.00

Market closed

HK$361.00

Day’s Range― - ―

52-Week RangeHK$165.50 - HK$563.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)1.60M

Market Cap

HK$32.28B

Enterprise ValueHK$5.84B

Total Cash (Recent Filing)HK$3.70B

Total Debt (Recent Filing)HK$67.89M

Price to Earnings (P/E)―

Beta1.02

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding89,415,410

10 Day Avg. Volume2,424,103

30 Day Avg. Volume1,602,164

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)-7.92

Price to Sales (P/S)8.25

P/FCF Ratio62.90

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$477.85

Price Target Upside32.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company maintains a solid cash balance of RMB3.75bn, which is sufficient to support continued R&D and pipeline expansion.

Industry RecognitionDualityBio's high-profile partnerships serve as industry validation of its platform and pipeline assets.

PartnershipsDualityBio's extensive partnerships with companies like BioNTech and GSK, totaling over US$6.0bn in potential deal value, are expected to provide sustained funding as clinical programs progress.

Pipeline InnovationDualityBio has a robust pipeline of in-house discovered antibody-drug conjugate (ADC) candidates which is a testament to the Company's prowess in ADC innovation.

Bears Say

Commercialization TimelineBioNtech and DualityBio plan to file NDAs for DB-1303/BNT323 in the US and China by end-2025, marking a major step towards commercialization.

Duality Biotherapeutics, Inc. News

Duality Biotherapeutics Shareholders Approve 2025 Equity Incentive Scheme and Mandate Limits

The latest update is out from Duality Biotherapeutics, Inc. ( ($HK:9606) ). Duality Biotherapeutics shareholders have approved the...

13d ago

9606

Duality Biotherapeutics Proposes 2025 Share Scheme to Boost Growth

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has provided an update. Duality Biotherapeutics, Inc. has announced its proposal to...

30d ago

9606

Duality Biotherapeutics Announces EGM for 2025 Share Scheme Approval

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has issued an update. Duality Biotherapeutics, Inc. has announced an extraordinary general...

30d ago

9606

Duality Biotherapeutics Announces Extraordinary General Meeting

The latest update is out from Duality Biotherapeutics, Inc. ( ($HK:9606) ). Duality Biotherapeutics, Inc. has announced the...

1M ago

9606

Duality Biotherapeutics Plans RMB Share Listing on Shanghai’s Sci-Tech Board

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has shared an update. Duality Biotherapeutics, Inc. has announced a proposal to...

3M ago

9606

Duality Biotherapeutics Gains Inclusion in Key Stock Indices

The latest update is out from Duality Biotherapeutics, Inc. ( ($HK:9606) ). Duality Biotherapeutics, Inc., a company incorporated...

4M ago

9606

Duality Biotherapeutics Achieves Key Milestone in Cancer Drug Trial

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has shared an announcement. Duality Biotherapeutics, Inc. announced that its Phase III...

4M ago

9606

Duality Biotherapeutics, Inc.: Strong Growth Potential and Innovation Drive Buy Rating

Duality Biotherapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jill Wu...

4M ago

Duality Biotherapeutics Reports Strong Pipeline Progress Amid Financial Losses

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has provided an update. Duality Biotherapeutics, Inc. announced its interim results for...

5M ago

9606

Duality Biotherapeutics Schedules Board Meeting for Interim Results

Duality Biotherapeutics, Inc. ( ($HK:9606) ) has shared an announcement. Duality Biotherapeutics, Inc. has announced a board meeting...

5M ago

9606

9606 FAQ

What was Duality Biotherapeutics, Inc.’s price range in the past 12 months?

Duality Biotherapeutics, Inc. lowest stock price was HK$165.50 and its highest was HK$563.50 in the past 12 months.

What is Duality Biotherapeutics, Inc.’s market cap?

Duality Biotherapeutics, Inc.’s market cap is HK$32.28B.

When is Duality Biotherapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Duality Biotherapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Duality Biotherapeutics, Inc. overvalued?

According to Wall Street analysts Duality Biotherapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Duality Biotherapeutics, Inc. pay dividends?

Duality Biotherapeutics, Inc. does not currently pay dividends.

What is Duality Biotherapeutics, Inc.’s EPS estimate?

Duality Biotherapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Duality Biotherapeutics, Inc. have?

Duality Biotherapeutics, Inc. has 89,415,410 shares outstanding.

What happened to Duality Biotherapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Duality Biotherapeutics, Inc.?

Currently, no hedge funds are holding shares in HK:9606

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Duality Biotherapeutics, Inc. Stock Smart Score

Neutral

Analyst Consensus

Strong Buy

Average Price Target:
HK$477.85 (32.37% Upside)

Top Smart Score Stocks >

Company Description

Duality Biotherapeutics, Inc.

Duality Biotherapeutics, Inc. operates as a clinical stage company. It focuses on the development of next generation antibody-drug conjugate therapeutics and duality immune toxin antibody conjugate therapeutic. The company was founded by Zhu Zhong Yuan on July 3, 2019 and is headquartered in Shanghai, China.

Duality Biotherapeutics, Inc. (9606) Earnings & Revenues

Historic Earnings Reports

9606 Stock 12 Month Forecast

Average Price Target

HK$477.85

▲(32.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"186":"HK$186","497":"HK$497","263.75":"HK$263.8","341.5":"HK$341.5","419.25":"HK$419.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":496.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$496.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":477.85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$477.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":455.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$455.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[186,263.75,341.5,419.25,497],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.2,313.4838461538461,328.7676923076923,344.0515384615384,359.3353846153846,374.61923076923074,389.9030769230769,405.18692307692305,420.47076923076924,435.75461538461536,451.03846153846155,466.3223076923077,481.6061538461538,{"y":496.89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.2,312.0192307692308,325.83846153846156,339.6576923076923,353.4769230769231,367.29615384615386,381.11538461538464,394.9346153846154,408.75384615384615,422.57307692307694,436.3923076923077,450.21153846153845,464.03076923076924,{"y":477.85,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.2,310.3046153846154,322.40923076923076,334.51384615384615,346.61846153846153,358.7230769230769,370.8276923076923,382.9323076923077,395.0369230769231,407.14153846153846,419.24615384615385,431.35076923076923,443.4553846153846,{"y":455.56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":187.2,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":187.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":195,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":363.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >